Compass Ion Advisors LLC Decreases Stock Position in Stryker Co. (NYSE:SYK)

Compass Ion Advisors LLC trimmed its holdings in shares of Stryker Co. (NYSE:SYK) by 40.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,093 shares of the medical technology company’s stock after selling 3,417 shares during the period. Compass Ion Advisors LLC’s holdings in Stryker were worth $1,823,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Harbor Investment Advisory LLC boosted its stake in shares of Stryker by 0.4% during the first quarter. Harbor Investment Advisory LLC now owns 6,982 shares of the medical technology company’s stock valued at $2,499,000 after purchasing an additional 31 shares during the period. Bremer Bank National Association increased its position in shares of Stryker by 4.0% during the fourth quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock worth $266,000 after acquiring an additional 34 shares during the period. Simon Quick Advisors LLC raised its stake in shares of Stryker by 3.0% during the fourth quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock valued at $347,000 after acquiring an additional 34 shares in the last quarter. Consolidated Portfolio Review Corp grew its stake in Stryker by 3.6% in the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock worth $294,000 after purchasing an additional 34 shares in the last quarter. Finally, FourThought Financial Partners LLC increased its holdings in Stryker by 3.3% during the 4th quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock worth $322,000 after purchasing an additional 34 shares during the period. Institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SYK. Needham & Company LLC upgraded Stryker from a “hold” rating to a “buy” rating and set a $392.00 price target on the stock in a research note on Wednesday, May 22nd. Robert W. Baird increased their price objective on shares of Stryker from $367.00 to $378.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. BTIG Research boosted their price objective on shares of Stryker from $366.00 to $369.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. UBS Group increased their target price on Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a research report on Wednesday, May 1st. Finally, TD Cowen boosted their price target on Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Four equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $370.58.

Stryker Trading Down 0.1 %

NYSE SYK opened at $340.25 on Monday. The stock has a market cap of $129.62 billion, a P/E ratio of 38.84, a P/E/G ratio of 2.68 and a beta of 0.89. The company has a current ratio of 1.71, a quick ratio of 0.99 and a debt-to-equity ratio of 0.56. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The company has a fifty day simple moving average of $337.38 and a two-hundred day simple moving average of $333.91.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, beating the consensus estimate of $2.36 by $0.14. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The business had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.10 billion. During the same quarter in the previous year, the business earned $2.14 EPS. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, analysts forecast that Stryker Co. will post 11.95 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date is Friday, June 28th. Stryker’s dividend payout ratio is presently 36.53%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.